Later, in 2008, the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial compared the effects of pioglitazone and glimepiride (an antidiabetic Insulin secretagogue) in 543 patients with diabetes mellitus and coronary disease. Here, INS is linked to diabetes mellitus.